Document Detail


Pharmacoeconomics of Alzheimer's disease (AD) treatment with cholinesterase inhibitors.
MedLine Citation:
PMID:  22476975     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Until more effective and especially disease-modifying treatments for Alzheimer's disease (AD) are available, the therapeutic arsenal consists of cholinesterase inhibitors for mild to moderate dementia and memantine for moderate to severe dementia. Health economic data make an important contribution to the planning of healthcare services and the estimation of the cost of drug reimbursement. As such, for cholinesterase inhibitors it is claimed that the direct cost of the drug itself is eclipsed by the cost savings associated with delaying institutionalisation or delaying the time of progression into a more severe disease state. The present manuscript reviews several factors contributing to the costs of AD, gives an overview of available studies claiming the cost-effectiveness of current AD treatments, highlights strengths and weaknesses of the aforementioned studies, and discusses the impact of (early) identification and treatment of AD. It is concluded that there still is a need for long-term follow-up data from prospective cohort studies before the cost-effectiveness of cholinesterase inhibitors for AD can be confirmed.
Authors:
Jan Versijpt
Related Documents :
18622365 - Metabolic syndrome and alzheimer's disease: a link to a vascular hypothesis?
18181435 - The seafood-nutrition-health paradigm of south pacific islanders.
23938255 - Loss of functional alpha-synuclein: a toxic event in parkinson's disease?
22719025 - Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence.
24662515 - Established and emerging biomarkers for the prediction of type 1 diabetes: a systematic...
16338075 - Adult soft tissue sarcomas: conventional therapies and molecularly targeted approaches.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-4-4
Journal Detail:
Title:  Acta neurologica Belgica     Volume:  -     ISSN:  0300-9009     ISO Abbreviation:  Acta Neurol Belg     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-4-5     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0247035     Medline TA:  Acta Neurol Belg     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Department of Neurology, UZ Brussel, Laarbeeklaan 101, 1090, Brussel, Belgium, jan.versijpt@uzbrussel.be.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Vascular calcification: pathophysiology and risk factors.
Next Document:  Associations of Zinc and Copper Levels in Serum and Hair with Sleep Duration in Adult Women.